The Rembra platform received 510(k) clearance from the U.S. Food and Drug Administration (FDA) earlier this year, including Rembra CT, Rembra RT and Areta RT. The newly cleared systems are designed to help healthcare providers respond to growing demand for imaging and radiation therapy planning by helping to improve speed, efficiency and access to high-quality imaging. As imaging volumes and clinical complexity continue to rise, healthcare providers need solutions that can help them work more efficiently while maintaining confidence in clinical decisions. The Rembra platform of systems also extends the role of CT across diagnostic radiology and radiation therapy, helping to enable more connected workflows and a coordinated approach to patient care – from rapid assessment in acute settings to precise cancer treatment planning. With a large 85 cm bore, Rembra CT is purpose-built for the front lines of care, enabling ultra-fast, high-throughput imaging in various settings including emergency departments, critical care and interventional settings. Its advanced acquisition and reconstruction capabilities support rapid, high-quality imaging at scale, helping clinicians make timely decisions in critical situations without compromising diagnostic confidence.
